Takeda sells Japan’s non-core products portfolio to Teijin Pharma
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
Metabolic Disorders
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products...
Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
Takeda Pharmaceutical Company has signed an agreement to divest a portfolio of five non-core prescription...
Calliditas takes control of Genkyotex: expanding the rare disease pipeline
Calliditas has acquired the controlling interest, 62.7%, of Genkyotex for €19.8m. This deal expands Calliditas’s...
Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?
Different from a gluten intolerance, coeliac disease causes long-term damage to patients’ small intestine and...
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
US-based Gain Therapeutics has signed a research partnership with Japan-headquartered Sumitomo Dainippon Pharma, leveraging the former’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to target previously undruggable allosteric binding sites.…
Takeda bets on Engitix’s ECM drug discovery platform for liver fibrosis
London-headquartered Engitix is partnering with pharma giant Takeda to discover and develop novel therapies for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH). The pair will leverage Engitix’s proprietary extracellular…
Novo Nordisk moves further into CV diseases with Corvidia acquisition
Danish pharma company Novo Nordisk has entered a definitive agreement to acquire Massachusetts-headquartered Corvidia Therapeutics. The deal involves an upfront payment of $725m, but Corvidia could be eligible to receive…
PTC acquires Censa: diversifying into metabolic disease
Rare disease-focused PTC Therapeutics has entered into an agreement to acquire Massachusetts-based Censa Pharmaceuticals. The deal centres around Censa’s lead product CNSA-001, an investigational therapy for rare metabolic diseases associated…
Label update for SGLT2-Is inhibitors following FDA safety review
The US Food and Drug Administration (FDA) has conducted a safety review of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is), resulting in a label update that recommends the discontinuation of these inhibitors before…
AstraZeneca Q&A: combatting shared risk factors in CVRM diseases
Cardiovascular (CV) diseases are the leading cause of death worldwide, according to the World Health Organisation. Part of the challenge of reducing the mortality rate of CV conditions is that…
